POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
A well-established safety profile.1
8% of patients discontinued POMALYST + dex due to adverse reactions.

aSerious adverse reactions were reported in at least 3 patients in the POM + Low-dose Dex arm, AND at least 1% higher than the High-dose Dex arm percentage.
Data cutoff: March 1, 2013
Grade 3 or 4 adverse reactions1
• (≥15% in the POMALYST + low-dose dex arm and ≥1% higher than the high-dose dex alone) included neutropenia (48%), thrombocytopenia (22%), and pneumonia (16%)
Dose modifications due to adverse reaction(s)1
• 67% of trial patients experienced at least one dose interruption of POMALYST, while 27% of patients experienced at least 1 dose reduction of POMALYST and 8% discontinued treatment with POMALYST
• The median time to first dose interruption and first dose reduction of POMALYST was 4.1 weeks and 4.5 weeks, respectively
The majority of patients remained on POMALYST + dex until disease progression or unacceptable toxicity with dose modifications.1,2
New occurrences of common (≥10%) adverse reactions decreased over the first 5 cycles of treatment.3

In the Phase 3 trial, patients in the POMALYST arm received a median of 5 treatment cycles.1
References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14(11)1055-1066. 3. Data on file. Celgene Corporation, a Bristol Myers Squibb company.